ACR Meeting Abstracts

ACR Meeting Abstracts

Abstract Number: 1638

Systemic Treatment in Behçet’s Disease According to Clinical Phenotypes. Study of 111 Patients

David Martinez-Lopez1, Lara Sanchez-Bilbao2, Carmen Alvarez-Reguera2, Alba Herrero Morant2, Inigo Gonzalez-Mazon3, José Luis Martín-Varillas4, Guillermo Suarez-Amorin2, Patricia Setien-Preciados2, Cristina Mata-Arnaiz5, Miguel Ángel González-Gay6 and Ricardo Blanco2, 1Hospital Universitario Marques de Valdecilla, Santander (SPAIN), Spain, 2Hospital Universitario Marques de Valdecilla, Santander, Spain, 3Hospital Universitario Marques de Valdecilla, Bezana, Spain, 4Hospital Sierrallana, Torrelavega, Spain, 5Hospital de Laredo, Santander, Spain, 6Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain

Meeting: ACR Convergence 2020

Keywords: , ,

Session Information

Date: Monday, November 9, 2020

Title: Miscellaneous Rheumatic & Inflammatory Diseases Poster III: Therapies

Session Type: Poster Session D

Session Time: 9:00AM-11:00AM

Background/Purpose: Behçet’s disease (BD) is a multisystemic vasculitis. Different clinical phenotypes can be distinguished. Systemic corticosteroids are the most used drugs in BD. Conventional and biological immunosuppressants (IS) may also be used. Objectives: To evaluate the systemic treatment of BD according to clinical domains

Methods: Study of all consecutive 111 patients diagnosed with definitive or possible BD by expert rheumatologists in a well-defined population of Northern Spain, between 1980 and 2019. Most of them met the International Criteria for BD (ICBD) Study of all consecutive 111 patients diagnosed with definitive or possible BD by expert rheumatologists in a well-defined population of Northern Spain, between 1980 and 2019. Most of them met the International Criteria for BD (ICBD).

Results: We studied 111 patients (62 women/49 men), mean age at diagnosis 36.8±13.2 years. After a mean follow-up of 81.4±85 months, all patients required systemic treatment (TABLE 1-2). Biological therapy (n=28) was indicated by ocular manifestations (n=13; 46.4%) persistent, severe and refractory oral ulcers (n=10, 35.7%), neurological (n=2; 7.1%), musculoskeletal (n=2; 7.1%) or cutaneous involvement (1; 3.6%). Adalimumab and Infliximab were the biological therapy more frequently used.

Conclusion: Most patients with BD required oral corticosteroids and colchicine. Almost half required conventional IS. Up to a third required biologic therapy, especially by ocular involvement. Most patients had clinical improvement.

Disclosure: D. Martinez-Lopez, Lilly, 2; L. Sanchez-Bilbao, None; C. Alvarez-Reguera, None; A. Herrero Morant, None; I. Gonzalez-Mazon, None; J. Martín-Varillas, None; G. Suarez-Amorin, None; P. Setien-Preciados, None; C. Mata-Arnaiz, None; M. González-Gay, None; R. Blanco, None.

To cite this abstract in AMA style:

Martinez-Lopez D, Sanchez-Bilbao L, Alvarez-Reguera C, Herrero Morant A, Gonzalez-Mazon I, Martín-Varillas J, Suarez-Amorin G, Setien-Preciados P, Mata-Arnaiz C, González-Gay M, Blanco R. Systemic Treatment in Behçet’s Disease According to Clinical Phenotypes. Study of 111 Patients [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/systemic-treatment-in-behcets-disease-according-to-clinical-phenotypes-study-of-111-patients/. Accessed .

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/systemic-treatment-in-behcets-disease-according-to-clinical-phenotypes-study-of-111-patients/